Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Intellia Therapeutics (NTLA) Revenue (2016 - 2025)

Intellia Therapeutics (NTLA) has disclosed Revenue for 11 consecutive years, with $23.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Revenue rose 78.79% to $23.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $67.7 million, a 16.92% increase, with the full-year FY2025 number at $67.7 million, up 16.92% from a year prior.
  • Revenue was $23.0 million for Q4 2025 at Intellia Therapeutics, up from $13.8 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $28.9 million in Q1 2024 to a low of -$1.9 million in Q4 2023.
  • A 5-year average of $12.0 million and a median of $12.9 million in 2021 define the central range for Revenue.
  • Peak YoY movement for Revenue: surged 4322.0% in 2022, then tumbled 114.12% in 2023.
  • Intellia Therapeutics' Revenue stood at $12.9 million in 2021, then grew by 5.59% to $13.6 million in 2022, then tumbled by 114.12% to -$1.9 million in 2023, then soared by 771.57% to $12.9 million in 2024, then surged by 78.79% to $23.0 million in 2025.
  • Per Business Quant, the three most recent readings for NTLA's Revenue are $23.0 million (Q4 2025), $13.8 million (Q3 2025), and $14.2 million (Q2 2025).